On April 7, 2022, Pfizer announced its plans to acquire ReViral, a biopharmaceutical company focused on the development of antiviral therapeutics in the fight against respiratory synctytial virus (RSV). This is exciting news for medicines development in general and Pfizer in particular, as it serves the company’s endeavor to address a worldwide unmet need for RSV treatments.

According to an article from BioPharm International, “Treatment options for RSV are extremely limited and focus primarily on supportive care,” said Annaliesa Anderson, PhD, senior vice president and chief scientific officer, Bacterial Vaccines and Hospital, at Pfizer. “The proposed acquisition of ReViral’s pipeline of therapeutic candidates is complementary to our efforts to advance the first vaccine candidate to help protect against this harmful disease. Combining the capabilities and expertise of our organizations will enable us to further the clinical development of a potential therapy for those with RSV disease…” 1

You can read the complete article here.


  • The material in these reviews is from various public open access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred


  1. Editors, BioPharm International. “Pfizer to Acquire Reviral and Its Respiratory Syncytial Virus Therapeutic Candidates.” BioPharm International, BioPharm International, 8 Apr. 2022, https://www.biopharminternational.com/view/pfizer-to-acquire-reviral-and-its-respiratory-syncytial-virus-therapeutic-candidates?qs=39a6c0071d54c7e5da550d4af2e8d5b7e84fc11440f04ebc44e108b35d52a7055e66f0598084f971a1eb2446698aeca8e540c2edff717c13.